1. Home
  2. PTY vs SUPN Comparison

PTY vs SUPN Comparison

Compare PTY & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pimco Corporate & Income Opportunity Fund

PTY

Pimco Corporate & Income Opportunity Fund

N/A

Current Price

$11.05

Market Cap

2.4B

Sector

Finance

ML Signal

N/A

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

N/A

Current Price

$42.63

Market Cap

2.5B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PTY
SUPN
Founded
N/A
2005
Country
United States
United States
Employees
N/A
778
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.4B
2.5B
IPO Year
2002
2010

Fundamental Metrics

Financial Performance
Metric
PTY
SUPN
Price
$11.05
$42.63
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
★ $61.75
AVG Volume (30 Days)
★ 1.7M
507.8K
Earning Date
01-01-0001
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
N/A
★ $392,755,000.00
Revenue This Year
N/A
$23.21
Revenue Next Year
N/A
$54.85
P/E Ratio
N/A
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$10.65
$40.51
52 Week High
$14.69
$59.68

Technical Indicators

Market Signals
Indicator
PTY
SUPN
Relative Strength Index (RSI) 37.74 47.74
Support Level N/A $42.54
Resistance Level $11.92 $52.33
Average True Range (ATR) 0.20 1.34
MACD -0.02 0.26
Stochastic Oscillator 38.79 61.76

Price Performance

Historical Comparison
PTY
SUPN

About PTY Pimco Corporate & Income Opportunity Fund

PIMCO Corporate & Income Opportunity Fds operates as a closed-end management investment company. It seeks to maximize total return through a combination of current income and capital appreciation. The fund invests a majority of the total assets in a combination of corporate debt obligations of varying maturities, other corporate income-producing securities, and income-producing securities of non-corporate issuers, such as U.S. Government securities, municipal securities, and mortgage-backed and other asset-backed securities issued on both public or private basis.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

Share on Social Networks: